Network Modeling Approaches and Applications to Unravelling Non-Alcoholic Fatty Liver Disease

被引:26
作者
Blencowe, Montgomery [1 ,2 ]
Karunanayake, Tilan [1 ]
Wier, Julian [1 ]
Hsu, Neil [1 ]
Yang, Xia [1 ,2 ,3 ]
机构
[1] Univ Calif Los Angeles, Dept Integrat Biol & Physiol, 610 Charles E Young Dr East, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Mol Cellular & Integrat Physiol Interdept Program, 610 Charles E Young Dr East, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, Interdept Program Bioinformat, 610 Charles E Young Dr East, Los Angeles, CA 90095 USA
基金
美国国家卫生研究院;
关键词
network modeling; integrative genomics; NAFLD; NASH; steatosis; systems biology; multi-omics; TYPE-2; DIABETES-MELLITUS; MOUSE DIVERSITY PANEL; INSULIN-RESISTANCE; GENE-EXPRESSION; SYSTEMS BIOLOGY; ADIPOSE-TISSUE; MITOCHONDRIAL DYSFUNCTION; CONFERS SUSCEPTIBILITY; CARDIOVASCULAR-DISEASE; SERIES LIPOTOXICITY;
D O I
10.3390/genes10120966
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Non-alcoholic fatty liver disease (NAFLD) is a progressive condition of the liver encompassing a range of pathologies including steatosis, non-alcoholic steatohepatitis (NASH), cirrhosis, and hepatocellular carcinoma. Research into this disease is imperative due to its rapid growth in prevalence, economic burden, and current lack of FDA approved therapies. NAFLD involves a highly complex etiology that calls for multi-tissue multi-omics network approaches to uncover the pathogenic genes and processes, diagnostic biomarkers, and potential therapeutic strategies. In this review, we first present a basic overview of disease pathogenesis, risk factors, and remaining knowledge gaps, followed by discussions of the need and concepts of multi-tissue multi-omics approaches, various network methodologies and application examples in NAFLD research. We highlight the findings that have been uncovered thus far including novel biomarkers, genes, and biological pathways involved in different stages of NAFLD, molecular connections between NAFLD and its comorbidities, mechanisms underpinning sex differences, and druggable targets. Lastly, we outline the future directions of implementing network approaches to further improve our understanding of NAFLD in order to guide diagnosis and therapeutics.
引用
收藏
页数:32
相关论文
共 50 条
  • [41] Non-alcoholic fatty liver disease is associated with cardiovascular disease risk markers
    Edens, M. A.
    Kuipers, F.
    Stolk, R. P.
    OBESITY REVIEWS, 2009, 10 (04) : 412 - 419
  • [42] An extended fatty liver index to predict non-alcoholic fatty liver disease
    Kantartzis, K.
    Rettig, I.
    Staiger, H.
    Machann, J.
    Schick, F.
    Scheja, L.
    Gastaldelli, A.
    Bugianesi, E.
    Peter, A.
    Schulze, M. B.
    Fritsche, A.
    Haering, H. -U.
    Stefan, N.
    DIABETES & METABOLISM, 2017, 43 (03) : 229 - 239
  • [43] Influence of non-alcoholic fatty liver disease on cardiovascular disease
    Ampuero, Javier
    Romero-Gomez, Manuel
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2012, 35 (08): : 585 - 593
  • [44] Pathogenesis and Therapeutic Strategies Related to Non-Alcoholic Fatty Liver Disease
    Teng, Tieshan
    Qiu, Shuai
    Zhao, Yiming
    Zhao, Siyuan
    Sun, Dequan
    Hou, Lingzhu
    Li, Yihang
    Zhou, Ke
    Yu, Xixi
    Yang, Changyong
    Li, Yanzhang
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (14)
  • [45] An adipocentric perspective on the development and progression of non-alcoholic fatty liver disease
    Lee, Eunyoung
    Korf, Hannelie
    Vidal-Puig, Antonio
    JOURNAL OF HEPATOLOGY, 2023, 78 (05) : 1048 - 1062
  • [46] Early life programming and the risk of non-alcoholic fatty liver disease
    Lynch, C.
    Chan, C. S.
    Drake, A. J.
    JOURNAL OF DEVELOPMENTAL ORIGINS OF HEALTH AND DISEASE, 2017, 8 (03) : 263 - 272
  • [47] Altered clot kinetics in patients with non-alcoholic fatty liver disease
    Hickman, Ingrid J.
    Sullivan, Clair M.
    Flight, Simone
    Campbell, Catherine
    Crawford, Darrell H.
    Masci, Paul. P.
    O'Moore-Sullivan, Trisha M.
    Prins, Johannes B.
    Macdonald, Graeme A.
    ANNALS OF HEPATOLOGY, 2009, 8 (04) : 331 - 338
  • [48] Applying Lipidomics to Non-Alcoholic Fatty Liver Disease: A Clinical Perspective
    Huang, Jian
    Sigon, Giordano
    Mullish, Benjamin H.
    Wang, Dan
    Sharma, Rohini
    Manousou, Pinelopi
    Forlano, Roberta
    NUTRIENTS, 2023, 15 (08)
  • [49] Non-alcoholic fatty liver disease. How and who to screen
    Teran Lantaron, Alvaro
    Crespo Garcia, Javier
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2011, 34 (04): : 278 - 288
  • [50] Recent insights on the role of cholesterol in non-alcoholic fatty liver disease
    Arguello, Graciela
    Balboa, Elisa
    Arrese, Marco
    Zanlungo, Silvana
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2015, 1852 (09): : 1765 - 1778